Lifecore Biomedical to Report Financial Results for First Quarter of Fiscal 2025 Prior to Market Open on October 4, 2024
Rhea-AI Summary
Lifecore Biomedical (NASDAQ: LFCR), a fully integrated contract development and manufacturing organization (CDMO), has announced that it will release its financial results for the first quarter of fiscal year 2025 on Friday, October 4, 2024, before the market opens. The company will also host a webcast at 8:30 a.m. Eastern Time on the same day.
During the webcast, Lifecore's senior management team will discuss the quarterly financial results and provide an update on recent corporate developments. Investors and interested parties can access the live webcast or archived version through the Investor Events & Presentations page on Lifecore's website at https://ir.lifecore.com/events-presentations.
Positive
- None.
Negative
- None.
News Market Reaction – LFCR
In the trading session that priced this news, LFCR gained 14.35%, reflecting a significant positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
AI-generated analysis. How Rhea-AI works. Not financial advice.
CHASKA, Minn., Oct. 03, 2024 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore”), a fully integrated contract development and manufacturing organization (“CDMO”), today announced that it will report financial results for the first quarter of fiscal year 2025 on Friday, October 4, 2024, prior to market open and will host a webcast at 8:30 a.m. Eastern Time. Members of Lifecore’s senior management team will discuss financial results for the first quarter and review recent corporate developments.
To listen to the live webcast, or access the archived webcast, please visit the Investor Events & Presentations page of Lifecore’s website at: https://ir.lifecore.com/events-presentations.
About Lifecore Biomedical
Lifecore Biomedical, Inc. (Nasdaq: LFCR) is a fully integrated contract development and manufacturing organization (CDMO) that offers highly differentiated capabilities in the development, fill and finish of sterile injectable pharmaceutical products in syringes, vials, and cartridges, including complex formulations. As a leading manufacturer of premium, injectable-grade hyaluronic acid, Lifecore brings more than 40 years of expertise as a partner for global and emerging biopharmaceutical and biotechnology companies across multiple therapeutic categories to bring their innovations to market. For more information about the company, visit Lifecore’s website at www.lifecore.com.
